These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 17093363)

  • 41. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
    Slatkin NE
    J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacogenetics of chemotherapy-induced nausea and vomiting.
    Sugino S; Janicki PK
    Pharmacogenomics; 2015 Jan; 16(2):149-60. PubMed ID: 25616101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Postoperative nausea and vomiting. Controversies, evidence and new drugs].
    Figueredo E
    Rev Esp Anestesiol Reanim; 2000 Feb; 47(2):81-9. PubMed ID: 10769555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Newer trends in the prevention or treatment of postoperative nausea and vomiting.
    Ouellette SM
    CRNA; 1999 Feb; 10(1):24-33. PubMed ID: 10504906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT
    Kovac AL
    Drugs; 2016 Dec; 76(18):1719-1735. PubMed ID: 27988869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ondansetron has similar clinical efficacy against both nausea and vomiting.
    Jokela RM; Cakmakkaya OS; Danzeisen O; Korttila KT; Kranke P; Malhotra A; Paura A; Radke OC; Sessler DI; Soikkeli A; Roewer N; Apfel CC
    Anaesthesia; 2009 Feb; 64(2):147-51. PubMed ID: 19143691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical selection of antiemetics.
    Flake ZA; Scalley RD; Bailey AG
    Am Fam Physician; 2004 Mar; 69(5):1169-74. PubMed ID: 15023018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?
    Trammel M; Roederer M; Patel J; McLeod H
    Curr Oncol Rep; 2013 Jun; 15(3):276-85. PubMed ID: 23512709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?
    Candiotti KA; Birnbach DJ; Lubarsky DA; Nhuch F; Kamat A; Koch WH; Nikoloff M; Wu L; Andrews D
    Anesthesiology; 2005 Mar; 102(3):543-9. PubMed ID: 15731591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-dose granisetron for postoperative nausea and vomiting prophylaxis.
    Corman SL; Skledar SJ; Ansani NT
    Ann Pharmacother; 2004 Apr; 38(4):710-3. PubMed ID: 14982978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
    Navari RM; Koeller JM
    Ann Pharmacother; 2003 Sep; 37(9):1276-86. PubMed ID: 12921512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dexamethasone plus ondansetron for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a comparison with dexamethasone alone.
    Bano F; Zafar S; Aftab S; Haider S
    J Coll Physicians Surg Pak; 2008 May; 18(5):265-9. PubMed ID: 18541078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Postoperative nausea and vomiting: rational algorithms for prevention and treatment based on current evidence].
    Kranke P; Eberhart LH
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Apr; 44(4):286-94; quiz 295. PubMed ID: 19367533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP; Madelaine I; Scotté F
    Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
    Gan TJ; Sinha AC; Kovac AL; Jones RK; Cohen SA; Battikha JP; Deutsch JS; Pergolizzi JV; ; Glass PS
    Anesth Analg; 2009 May; 108(5):1498-504. PubMed ID: 19372328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients.
    Yamada Y; Sugiura M; Higo K; Ozeki T; Takayanagi R; Okuyama K; Yamamoto K; Satoh H; Sawada Y; Iga T
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):185-90. PubMed ID: 15168080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of current antiemetic practices on patient outcomes: a prospective study on high-risk patients.
    White PF; O'Hara JF; Roberson CR; Wender RH; Candiotti KA;
    Anesth Analg; 2008 Aug; 107(2):452-8. PubMed ID: 18633023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
    Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
    Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, double-blinded comparison of ondansetron, granisetron, and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy.
    Jain V; Mitra JK; Rath GP; Prabhakar H; Bithal PK; Dash HH
    J Neurosurg Anesthesiol; 2009 Jul; 21(3):226-30. PubMed ID: 19543000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
    Lajolo PP; de Camargo B; del Giglio A
    Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.